ReviewCancer gene therapy2005
RNA interference and potential therapeutic applications of short interfering RNAs.
Review in Cancer gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 124 citations in OpenAlex.
- RNA Vaccines: Yeast as a Novel Antigen Vehicle.Vaccines · 2023Review
- Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies.Cancers · 2022Review
- Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics.Pharmaceutics · 2021Review
- Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras.Experimental and therapeutic medicine · 2019Article
- Thymosin Beta 4 Is Involved in the Development of Electroacupuncture Tolerance.Frontiers in cellular neuroscience · 2019Article
- RNAi technique, how far is it from pediatrics?Pediatric investigation · 2017Article
- Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma.Oncotarget · 2017Article
- Proof-of-concept study: profile of circulating microRNAs in Bovine serum harvested during acute and persistent FMDV infection.Virology journal · 2017Article
- Inhibition of cell proliferation and migration after HTRA1 knockdown in retinal pigment epithelial cells.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2015Article
- Inhibition of monocyte adhesion to brain-derived endothelial cells by dual functional RNA chimeras.Molecular therapy. Nucleic acids · 2014Article
- Cationic liposome-nucleic acid complexes for gene delivery and gene silencing.New journal of chemistry = Nouveau journal de chimie · 2014Article
- Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease.CNS neuroscience & therapeutics · 2014Article
- Chikungunya virus: an update on antiviral development and challenges.Drug discovery today · 2013Review
- Synthetic microRNA-mediated downregulation of Nogo-A in transgenic rats reveals its role as regulator of synaptic plasticity and cognitive function.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Liquid crystal assemblies in biologically inspired systems.Liquid crystals · 2013Article
- Lipid-based vectors for siRNA delivery.Journal of drug targeting · 2012Review
- Synthesis and preliminary investigations of the siRNA delivery potential of novel, single-chain rigid cationic carotenoid lipids.Molecules (Basel, Switzerland) · 2012Article
- Effective endogenous gene silencing mediated by pH responsive peptides proceeds via multiple pathways.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Cationic liposome-nucleic acid complexes: liquid crystal phases with applications in gene therapy.Liquid crystals · 2011Article
- Nanogyroids incorporating multivalent lipids: enhanced membrane charge density and pore forming ability for gene silencing.Langmuir : the ACS journal of surfaces and colloids · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference is an endogenous gene-silencing mechanism that involves double-stranded RNA-mediated sequence-specific mRNA degradation. The discovery of this pathway together with the elucidation of the structure and function of short interfering RNAs--the effector molecules of RNA interference--has had an enormous impact on experimental biology. RNA interference technologies are currently the most widely utilized techniques in functional genomic studies. Furthermore, there is an intense research effort aimed at developing short interfering RNAs for therapeutic purposes. A number of proof-of-principle experiments have demonstrated the clinical potential of appropriately designed short interfering RNAs in various diseases including viral infections, cancer and neurodegenerative disorders. Already, in such a short time from their discovery, Acuity Pharmaceuticals (August 2004) and Sirna Therapeutics (September 2004) have filed Investigational New Drug applications with the US FDA to begin clinical trials with modified siRNA molecules in patients with age-related macular degeneration. This review will give a brief overview of the mechanism of RNA interference and applications of the pathway in experimental biology will be discussed. The article will focus on recent developments related to the use of RNA interference technologies in mammalian systems and on potential clinical applications of short interfering RNA-mediated RNA interference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.